Loss of Efficacy After Freezing Tirzepatide needs to be stable to lower blood sugar and support weight control
The authors concluded: The use of GLP-1 agonists should be considered in T1DM patients who are overweight or obese and not at glycemic goals despite aggressive insulin therapy. After conducting clinical trials with a GLP-1 agonist, Novo Nordisk decided not to pursue FDA approval for treating type 1 diabetes
Interestingly, while the weights of four different skeletal muscles were measured, no significant changes were observed, although a trend toward decreased muscle mass was noted
It does not replace clinical judgement, medication decisions, dietetic support or follow-up care
Why does the formulation choice matter for dosing
2 The logic is elegant: after a carbohydrate-rich meal, most of the glycemic excursion is governed not by how fast the pancreas secretes insulin but by how fast glucose arrives in the small intestine to be absorbed